Significantly Fewer Major Noncerebral Bleeds

	In ASSENT-2, there were 20% fewer major noncerebral bleeding events* in patients treated with TNKase vs. Activase® (Alteplase)1
	Significantly fewer blood transfusions were required in patients treated with TNKase vs. Activase (p=0.0002)1
	The need for fewer blood transfusions may potentially alleviate the risk of additional complications, and reduce the need for institutional resources
	The most frequent adverse reaction associated with TNKase is bleeding. Should serious bleeding occur, concomitant heparin and antiplatelet therapy should be discontinued immediately.
*	Major bleeding is defined as bleeding requiring blood transfusion or leading to hemodynamic compromise.

Indication: For use in mortality reduction associated with acute myocardial infarction (AMI). Treatment should be initiated as soon as possible after the onset of AMI symptoms.

Safety Information: TNKase therapy is contraindicated in the following conditions due to an increased risk of bleeding: active internal bleeding, history of cerebrovascular accident, intracranial or intraspinal surgery or trauma within 2 months, intracranial neoplasm, arteriovenous malformation, or aneurysm, known bleeding diathesis, and severe uncontrolled hypertension.

All thrombolytic agents increase the risk of bleeding, including intracranial bleeding, and should be used only in eligible patients. In addition, thrombolytic therapy increases the risk of stroke, including hemorrhagic stroke, particularly in elderly patients. In patients with large ST segment elevation myocardial infarction, physicians should choose either thrombolysis or percutaneous coronary intervention (PCI) as the primary treatment strategy for reperfusion. Rescue PCI or subsequent elective PCI may be performed after administration of thrombolytic therapies if medically appropriate.